BLCOBausch + Lomb Corporation
Is the price fair?
Priced for +15% a year vs +11% a year delivered. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~15% a year FCF growth. The price demands more than its three-year revenue growth of 11% a year, priced for acceleration.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What BLCO's price assumes
Bausch + Lomb Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 1.07× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.4%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
- Growth the price implies
- +15%
Growth the price implies · The price pays for +15% free cash flow growth a year for a decade; revenue has grown +11% a year over the last three.
- Price / book
- 0.89
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 0.89
- EV / EBITas of 2026-Q2
- 32.2
- EV / salesas of 2026-Q2
- 1.95
- Free cash flow, trailing twelve months
- $137M
- Market capitalisation
- $5.67B
- 3-year revenue growth
- +11%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #8 of 21 by RyuScore